Skip to main content
Equibles

XRTX · XORTX Therapeutics Inc. · Documents

Track XRTX — free

Use XRTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research XRTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.89 -0.03 (-3.59%)
Rebalance outlook locked
Market Cap
$1.67M
Shares
1.82M
Volume · Nov 12 641.44K Avg daily vol (3M) 722.89K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $2.66M 20-F filed Mar 20, 2026
2026
Oct 8
Current report 6-K
Current report

XORTX Therapeutics Inc. plans a Health Canada application for XRx-026, supporting a two-part XRX-OXY-102 study evaluating XORLO™ for gout; conducting the first part in Canada is expected to accelerate clinical data for a planned FDA New Drug Application.

Mar 20
Annual report 20-F FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $2.66M Diluted EPS -$0.56
2025
Showing 1–50 of 201 documents
Key facts CIK 1729214 CUSIP 98420Q405 13F (30d) 3 filings 3 filers Visit website Investor relations